Filing Flows

Filing Flows › Guardant Health (GH) › Next earnings date

Guardant Health (GH) earnings: beat the estimate

Guardant Health (GH) reported on Nov 5, 2026 and beat the EPS estimate: −$0.29 against −$0.31 (+7.8%). Revenue was $361M for Q3 2026, +36% year over year. It beat the EPS estimate in 60% of the quarters on record.

Last result+7.8% vs estimate
Beat rate60%

The last report

Guardant Health reported revenue of $361M for the third quarter 2026 (+36% Y/Y), net loss $124M: Oncology $231M, Screening $67.6M, Biopharma and data $59.0M, Licensing and other $3.1M. How it makes money → · Every quarter →

Guardant Health: EPS against the estimate, last 5 reportsGuardant Health: EPS against the estimate, last 5 reportsEstimateReported−$0.49−$0.39Oct 25−$0.47−$0.50Feb 26−$0.47−$0.45May 26−$0.39−$0.42Jul 26−$0.31−$0.29Nov 26
Latest (Nov 26): Estimate −$0.31, Reported −$0.29.
GH: the stock's move on each reportGH: the stock's move on each reportJul 30, 2026+12.4%May 7, 2026+3.7%Feb 19, 2026-4.0%Oct 29, 2025+32.8%

Guardant Health's latest quarter

Guardant Health, Q3 2026: revenue $361M (+36% year over year), operating margin -36.8%, net loss $124M, operating cash flow −$23.7M. The chart follows the revenue to costs, profit and cash.

Questions

Did Guardant Health beat earnings?

Guardant Health (GH) reported on Nov 5, 2026 and beat the EPS estimate: −$0.29 against −$0.31 (+7.8%).

When does GH report earnings?

The next date is not set yet.

Does Guardant Health usually beat earnings?

It beat the consensus EPS estimate in 60% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.